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Background: A single nucleotide polymorphism (SNP) in the epidermal growth factor (EGF) 
gene (rs4444903) has been associated with increased risk of cancer, including hepatocellular 
carcinoma (HCC). The aim of this study was to examine the relationship between the EGF SNP 
genotype and the development and prognosis of HCC, in a Japanese population.
Methods: Restriction fragment-length polymorphism was used to determine the presence of 
the EGF SNP genotype in 498 patients, including 208 patients with HCC. The level of EGF 
messenger ribonucleic acid (mRNA) expression in cancerous tissues was measured by quanti-
tative reverse transcription polymerase chain reaction. The correlation between the EGF SNP 
genotype and prognosis was statistically analyzed in the patients with HCC.
Results: The proportion of the A/A, A/G, and G/G genotypes were 5.3%, 42.8%, and 51.9%, 
respectively, in the patients with HCC, whereas in those without HCC, they were 8.6%, 35.9%, 
and 55.5%, respectively, revealing that the odds ratio (OR) of developing HCC was higher in 
patients with a G allele (OR =1.94, P=0.080 for A/G patients and OR =1.52, P=0.261 for G/G 
patients, as compared with A/A patients). In particular, when the analysis was limited to the 
363 patients with hepatitis C, the OR for developing HCC was 3.54 (P=0.014) for A/G patients 
and was 2.85 (P=0.042) for G/G patients, as compared with A/A patients. Tumoral EGF mRNA 
expression in G/G patients was significantly higher than that in A/A patients (P=0.033). No 
statistically significant differences were observed between the EGF SNP genotype and disease-
free or overall survival.
Conclusion: The EGF SNP genotype might be associated with a risk for the development of 
HCC in Japanese patients but not with prognosis. Of note, the association is significantly stronger 
in patients with hepatitis C, which is the main risk factor for HCC in Japan.
Keywords: epidermal growth factor, functional polymorphism, hepatocellular carcinoma, 
hepatitis C, hepatocarcinogenesis
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the 
seventh in women and the third most common cause of death from cancer worldwide.1 
The regions of high incidence for this disease are generally Eastern and South Eastern 
Asia and Middle and Western Africa. Because most patients who develop HCC are 
affected with viral hepatitis and require follow up for decades, it is necessary to analyze 
new molecular markers that can be used to identify high-risk populations that may 
be suitable for more intensive screening or prevention strategies.2
Currently, molecular alterations in tumors are being scrutinized at a genome-wide 
scale, covering different dimensions, such as gene expression, epigenetic changes, 
chromosomal aberrations, and more recently, next generation sequencing.3 As for 
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HCC, there have been many reports regarding molecular 
markers associated with the development of HCC.2,4–6 These 
molecular markers could be useful in the clinic; however, 
racial differences have been reported, and these need to be 
examined more thoroughly.5–7
Epidermal growth factor (EGF) was isolated in 1962 
and has been shown to stimulate the proliferation and dif-
ferentiation of epidermal and epithelial tissues, via binding 
to the EGF receptor (EGFR).8–10 EGF is well known to be 
associated with various malignant tumors, such as mela-
noma and esophageal carcinoma, via autocrine or paracrine 
pathways.11,12 Shahbazi et al13 identified a single nucleotide 
polymorphism (SNP) involving A to G transition at position 
61 in the 5′ untranslated region of the EGF gene (rs4444903) 
and demonstrated that the G/G genotype was associated 
with an increased risk of developing malignant melanoma 
compared with the A/A genotype.
Recently, Tanabe et al2 showed that the G/G genotype 
was correlated with an increased risk of developing HCC in 
both a mixed North American population and a Caucasian 
French population and that serum and liver tissue EGF levels 
were higher in A/G and G/G patients as compared with 
A/A patients. Furthermore, Abu Dayyeh et al7 expanded this 
study with a larger cohort and demonstrated the differences 
in the distribution of polymorphisms by race and by the 
incidence of HCC. However, conflicting results have been 
reported from the People’s Republic of China, with two stud-
ies showing an association between the G allele and HCC 
risk,14,15 while another report found no association between 
the EGF polymorphism and HCC risk.16
Thus far, there has been no report examining the EGF gen-
otype and its association with HCC in a Japanese population. 
Even though the allelic distribution is expected to be similar 
between Chinese and Japanese patients, hepatitis C virus 
(HCV) is the major risk factor for HCC in Japan, whereas 
hepatitis B virus (HBV) is the major risk factor in the People’s 
Republic of China and other Eastern countries. The aim of 
this study was to investigate the relationship between the 
EGF SNP and risk of HCC. In addition, to our knowledge, 
this is the first report to analyze the EGF SNP as a prognostic 
factor for HCC patients.
Materials and methods
study population and specimens
A total of 498 patients with liver disease were single ethnic 
Japanese and retrospectively enrolled in this study at Nagoya 
University Hospital during the period from 1994 to 2010, 
with exclusion of autoimmune liver disease, hereditary liver 
diseases, including Wilson’s disease, drug-related hepatitis, 
and obstructive jaundice. Of these, 208 patients were diag-
nosed histologically as having HCC and underwent liver 
resection, and the other 290 patients were followed up for 
either hepatitis or liver cirrhosis. Patient’s clinicopatho-
logical parameters were collected retrospectively from our 
database. Postoperative disease-free and overall survival in 
the 208 patients who underwent liver resection were calcu-
lated, and the median follow-up duration was 40.9 months 
(range 0.4–209.0 months).
In the 208 patients who underwent liver resection, the col-
lected samples from the resected specimen were stored imme-
diately in liquid nitrogen at −80°C until analysis. Genomic 
deoxyribonucleic acid (DNA) was obtained by digestion with 
proteinase K, recombinant, PCR grade (F Hoffman-La Roche 
Ltd, Basel, Switzerland) followed by phenol/chloroform (Ultra-
Pure™ Phenol, Life Technologies Corp, Carlsbad, CA, USA/
Wako Pure Chemical Industries Ltd, Osaka, Japan) extraction. 
Total ribonucleic acid (RNA) was isolated from each of the 
frozen samples with the RNeasy® Mini Kit (Qiagen, Venlo, 
the Netherlands), according to the manufacturer’s protocol. For 
the 290 patients without liver resections, genomic DNA was 
extracted from 150 µL of whole blood, using a commercial 
kit (QIAamp DNA Blood Mini Kit; Qiagen).
As required by the Institutional Review Board of Nagoya 
University, which provided ethical approval, written and 
informed consent was obtained from all patients.
egF genotyping
The EGF SNP rs4444903 was analyzed by using restriction 
fragment-length polymorphism (RFLP), as described previous-
ly.13 In brief, genomic DNA was subjected to polymerase chain 
reaction (PCR) amplification using the GeneAmp® PCR Sys-
tem 9700 (Life Technologies Corp, Carlsbad, CA, USA). It was 
performed under the following conditions: initial denaturation 
at 95°C for 5 minutes, followed by 35 cycles at 95°C for 30 sec-
onds, at 51°C for 30 seconds, and 72°C for 1 minute, with a 
final extension step of 7 minutes at 72°C, to amplify nucleotide 
positions −78 to +164 of the EGF gene. The following primers 
were used, forward: 5′-TGTCACTAAAGGAAAGGAGGT-3′ 
and reverse: 5′-TTCACAGAGTTTAACAGCCC-3′ (STAR 
Oligo, Rikaken Co., Ltd, Nagoya, Japan). Then, 20 µL of 
PCR product was digested overnight with 5 units of AluI (F 
Hoffmann-La Roche Ltd) at 37°C, separated by electrophoresis 
in a 3% agarose gel (Agarose for DNA/RNA, NIPPON Genet-
ics Co., Ltd, Tokyo, Japan), and visualized by staining with 
ethidium bromide (Boehringer, Mannheim, IN, USA). AluI 
digestion of the 242 base pair (bp) PCR product containing 
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Figure 1 egF snP was analyzed by using restriction fragment-length polymorphism, 
and the representative results are shown: (A) hcc patients and (B) not hcc 
patients with liver disease other than hcc, including hepatitis or cirrhosis patients.
Abbreviations: bp, base pair; egF, epidermal growth factor; hcc, hepatocellular 
carcinoma; snP, single nucleotide polymorphism.
Table 1 Patient characteristics with or without hcc
HCC  
(n=208)
Not HCC  
(n=290)
P-value
age (years), mean ± sD 63.1±9.9 52.7±13.2 ,0.001
sex (male/female) 176/32 169/121 ,0.001
child−Pugh score (a/B/c) 193/15/0 265/18/7 0.674b
etiology, n (%)
 hBV 44 (68.8%) 20 (31.3%) ,0.001c
 hcV 130 (33.3%) 261 (66.8%)
 alcohol 0 (0.0%) 3 (100.0%)
 Multiple factorsa 3 (60.0%) 2 (40.0%)
 non-B, non-c 31 (88.6%) 4 (11.4%)
Notes: statistical differences between the hcc and not hcc groups were 
evaluated using the χ2 test for qualitative variables, and unpaired t-test for quantitative 
variables. aMultiple factors in hBV, hcV, and alcohol; bcomparison between child−
Pugh score a and B or c; ccomparison between hBV and hcV.
Abbreviations: hcc, hepatocellular carcinoma; hBV, hepatitis B virus; hcV, 
hepatitis c virus; sD, standard deviation.
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the 61*G allele produced 15, 34, and 193 bp fragments, while 
digestion of the 61*A allele produced 15, 34, 91, and 102 bp 
fragments. The experiment was repeated twice for each sample 
to ensure accuracy.
Determining egF mrna expression
The EGF messenger RNA (mRNA) in the HCC tissues 
was measured by quantitative reverse transcription-PCR. 
Total RNA from each sample was used to synthesize 
complementary DNA by single-strand reverse transcription 
(M-MLV Reverse Transcriptase; Life Technologies Corp). 
The level of EGF mRNA was expressed as the ratio of 
EGF mRNA PCR product to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) in each sample for standard-
ization. The primer sequences used were EGF forward: 
5′-CTTGTCATGCTGCTCCTCCT-3′ and reverse: 5′-GAG-
GGCATATGAAAGCTTCG-3′. The expression of GAPDH 
was quantified using the primer, forward: 5′-AACGGCTC-
CGGCATGTGCAA-3′ and reverse: 5′-GGCTCCTGTG-
CAGAGAAAGC-3′. Real-time detection of the emission 
intensity of SYBR® Green I (SYBR® Premix Ex Taq™ II, 
Takara Bio Inc, Otsu, Japan) was performed with an ABI 
Prism® 7000 Sequence Detection System (Life Technologies 
Corp). All PCR reactions were performed under the follow-
ing conditions: initial denaturation at 95°C for 30 minutes, 
followed by 40 cycles at 95°C for 15 seconds and 60°C for 
40 seconds. The experiments were performed in triplicate 
to ensure accuracy.
statistical analysis
The chi-square test was used to determine whether the 
observed genotype frequencies were consistent with 
Hardy–Weinberg equilibrium. The statistical differences 
between groups were evaluated using the chi-square test 
for qualitative variables and unpaired t-test or analysis of 
variance (ANOVA) for quantitative variables. Comparisons 
of groups with regard to the odds of HCC were made 
using a logistic regression model, and age and sex were 
included as covariates, in addition to genotype, in adjusted 
analysis. The overall survival and disease-free survival 
rates were calculated using the Kaplan–Meier method, 
and the difference was analyzed using the logrank test. 
Independent prognostic factors were analyzed with the 
Cox proportional hazards regression model, in a stepwise 
manner. The statistical analysis was performed using 
JMP® 9 software (SAS Institute Inc, Cary, NC, USA). 
The presence of a statistically significant difference was 
denoted by P,0.05.
Results
egF genotyping of patients
RFLP was used to determine the EGF SNP genotype in 208 
patients with HCC and 290 patients with either hepatitis or 
liver cirrhosis (Figure 1A and B). The ratios of A/A, A/G, and 
G/G genotypes were 5.3%, 42.8%, and 51.9%, respectively, 
in the 208 patients with HCC, whereas in the 290 patients 
OncoTargets and Therapy 2013:6
Table 2 Patient characteristics, stratified by EGF genotype
A/A  
(n=36)
A/G  
(n=193)
G/G  
(n=269)
P-value
age (years),  
mean ± sD
56.4±14.1 56.2±13.2 57.7±12.6 0.487
sex  
(male/female)
26/10 143/50 176/93 0.125
child−Pugh  
score (a/B/c)
33/1/2 176/13/4 249/19/1 0.865b
etiology, n (%)
 hBV 8 (22.2%) 28 (14.5%) 28 (10.4%) 0.127c
 hcV 26 (72.2%) 148 (76.7%) 217 (80.7%)
 alcohol 0 (0.0%) 0 (0.0%) 3 (1.1%)
 Multiple factorsa 0 (0.0%) 0 (0.0%) 5 (1.9%)
 non-B, non-c 2 (5.6%) 17 (8.8%) 16 (6.0%)
Notes: The statistical differences between each group were evaluated using the χ2 
test for qualitative variables, and anOVa for quantitative variables. aMultiple factors 
in hBV, hcV, and alcohol; bcomparison between the child−Pugh score a and B 
or c; ccomparison between hBV and hcV.
Abbreviations: anOVa, analysis of variance; egF, epidermal growth factor; hBV, 
hepatitis B virus; hcV, hepatitis c virus; sD, standard deviation.
A/A A/G
E
G
F
 m
R
N
A
 e
xp
re
ss
io
n
 le
ve
l
G/G
P=0.069
P=0.033
Figure 2 egF mrna expression level based on the genotypes in hcc patients.
Abbreviations: egF, epidermal growth factor; hcc, hepatocellular carcinoma; 
mrna, messenger ribonucleic acid.
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without HCC, the ratios were 8.6%, 35.9%, and 55.5%, 
respectively. The frequencies of the EGF polymorphism in 
this study population were consistent with Hardy–Weinberg 
equilibrium (P=0.864).
Patient characteristics
Our Japanese population consisted of 208 patients with 
HCC and 290 patients without HCC, and their charac-
teristics are shown in Table 1. There was a significant 
difference in the distribution of age (P,0.001) and sex 
(P,0.001) between the HCC group and those patients 
without HCC. There was also a significantly higher inci-
dence rate of HCC in the HBV patients than in the HCV 
patients (P,0.001).
The patient characteristics were also stratified by EGF 
genotype and are shown in Table 2. There were no significant 
differences in age and sex with respect to the EGF SNP. A 
total of 391 patients had HCV, and 64 patients had HBV, and 
there were no significant differences between these etiologies 
and EGF genotype (P=0.127).
egF mrna expression level
The presence of the G allele has been reported to increase 
the expression of EGF and may be one mechanism by 
which the EGF SNP increases the risk of HCC.2 To examine 
the correlation between EGF genotype and its expression, 
the level of EGF mRNA in cancerous tissues were measured 
by real-time PCR. The relative ratios of A/G (P=0.069) and 
G/G (P=0.033) patients were significantly higher than that 
of A/A patients (Figure 2).
relative risk of developing hcc,  
based on egF genotype
In order to explore the association between EGF genotype 
and the susceptibility of HCC development, the odds ratio 
(OR) for the risk of HCC was statistically analyzed, using 
the A/A genotype as a reference (Table 3). The proportions 
of A/A, A/G, and G/G genotypes were 5.3%, 42.8%, and 
51.9%, respectively, in patients with HCC, whereas in patients 
without HCC, the ratios were 8.6%, 35.9%, and 55.5%, 
respectively, which revealed that the OR of developing HCC 
was 1.93 (95% confidence interval [CI]: 0.92–4.27, P=0.081) 
in the A/G patients and was 1.51 (95% CI: 0.73–3.30, 
P=0.268) in the G/G patients, compared with A/A patients. 
Importantly, after adjusting for age and sex, the ORs for 
the A/G and G/G genotypes were 2.57 (P=0.030) and 1.90 
(P=0.133), respectively.
Next, we restricted the analysis to patients with HCV, 
which is the most common risk factor for HCC in Japan 
(Table 4). This analysis demonstrated a significant associa-
tion between the EGF genotype and risk of HCC. The OR was 
3.54 (P=0.014) in the A/G patients and 2.85 (P=0.042) in the 
G/G patients in the crude analysis, and was 7.58 (P,0.001) 
OncoTargets and Therapy 2013:6
Table 3 analysis of egF genotype in a Japanese population
HCC (n=208) 
n (%)
Not HCC (n=290) 
n (%)
Crude analysis Adjusted analysisb
OR (95% CI) P-valuea OR (95% CI) P-valuea
genotype
 a/a 11 (5.3%) 25 (8.6%) 1 [reference] 1 [reference]
 a/g 89 (42.8%) 104 (35.9%) 1.94 (0.93−4.32) 0.080 2.68 (1.10−6.32) 0.024
 g/g 108 (51.9%) 161 (55.5%) 1.52 (0.74−3.35) 0.261 1.93 (0.84−4.65) 0.122
allele
 a 111 (26.7%) 154 (26.6%) 1 [reference]
 g 305 (73.3%) 426 (73.4%) 0.99 (0.75−1.32) 0.963
Notes: comparisons of the groups with regard to the odds of hcc were made using a logistic regression model, and age and sex were included as covariates, in addition 
to genotype, in adjusted analysis. alogistic regression model; bage and sex were included as covariates in adjusted analysis.
Abbreviations: CI, confidence interval; EGF, epidermal growth factor; HCC, hepatocellular carcinoma; OR, odds ratio.
Table 4 analysis of egF genotype in Japanese patients with hcV
HCC with HCV (n=130) 
n (%)
HCV (n=233) 
n (%)
Crude analysis Adjusted analysisb
OR (95% CI) P-valuea OR (95% CI) P-valuea
genotype
 a/a 4 (3.1%) 21 (9.0%) 1 [reference] 1 [reference]
 a/g 56 (43.1%) 83 (35.6%) 3.54 (1.27–12.63) 0.014 7.58 (2.30–30.43) ,0.001
 g/g 70 (53.9%) 129 (55.3%) 2.85 (1.03–10.0) 0.042 4.61 (1.46–17.87) 0.008
allele
 a 64 (26.6%) 125 (26.8%) 1 [reference]
 g 196 (75.4%) 341 (73.2%) 1.12 (0.79–1.59) 0.516
Notes: The analysis was limited to the 363 patients with hcV. comparisons of the groups with regard to the odds of hcc were made using a logistic regression model, 
and age and sex were included as covariates, in addition to genotype, in adjusted analysis. alogistic regression model; bage and sex were included as covariates in adjusted 
analysis.
Abbreviations: CI, confidence interval; EGF, epidermal growth factor; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; OR, odds ratio.
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in the A/G patients and 4.61 (P=0.008) in the G/G patients 
in the adjusted analysis.
We also analyzed the risk limited to HBV, which is the 
second most frequent cause of HCC in Japan and accounts 
for about 15% of cases. The proportions of A/A, A/G, and 
G/G genotypes were 11.4%, 40.9%, and 47.7%, respectively, 
in patients with both HBV and HCC, while the proportions 
were 3.1%, 43.1%, and 53.9%, respectively, in patients 
with both HCV and HCC. Even though the A allele tended 
to occur more frequently in HBV patients with HCC, there 
was no significant difference compared with that proportion 
in patients with both HCV and HCC (P=0.136). In addition, 
the EGF genotype was not a significant risk factor for HCC 
in HBV patients (data not shown).
Univariate and multivariate analysis  
of clinicopathological factors  
for overall survival
In the univariate analysis of various clinicopathologi-
cal parameters for overall survival, tumor size ($3 cm) 
(P=0.009), vascular invasion (P,0.001), pathological stage 
III or IV (P=0.048), and alpha-fetoprotein (AFP) level 
($20 ng/mL) (P=0.015) were all significant risk factors for 
poor overall survival (Table 5). In the multivariate analy-
sis, tumor size, vascular invasion, and AFP level were all 
independent risk factors for poor survival. No statistically 
significant differences were observed between the EGF SNP 
genotype or EGF mRNA expression and overall survival, 
and the disease-free and overall survival stratified by EGF 
SNP, in the resected HCC patients, are shown in Figure 3.
Discussion
Hepatocarcinogenesis is thought to be deeply associated with 
chronic HBV or HCV infection, and in fact, a certain propor-
tion of chronically infected HBV and HCV individuals will 
develop HCC. Thus, multiple genetic and epigenetic factors 
may affect HCC development in this background.17 Among 
these genetic alterations, the dysregulation of EGF/EGFR 
signaling pathway is thought to be one of the most important 
factors in early hepatocarcinogenesis.18,19
Previously, it has been reported in several studies 
that the distribution of the EGF polymorphism varies by 
race.2,7,14,16,20 In our Japanese population, the allelic fre-
quencies of the G allele and A allele were 0.73 and 0.27, 
respectively, which is very similar to what has been reported 
for Chinese and African Americans. This distribution is 
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strikingly different from Caucasians though, for whom 
the allelic frequencies of the G and A alleles are roughly 
0.40 and 0.60, respectively. It is interesting to speculate 
that these differences in distribution might explain the 
high incidence of HCC in East Asia and Africa, but this 
requires further study.
A meta-analysis of five studies examining the EGF geno-
type and HCC risk concluded that the G allele was a risk 
factor for HCC, independently of ethnicity and etiology.21 
This is in contrast to three previous studies examining the 
association between the EGF genotype and risk of HCC 
in Chinese patients with HBV.14–16 However, a more recent 
meta-analysis examined six studies including these Chinese 
studies and revealed a significant association between the 
G allele and HCC risk, and concluded that the original dis-
crepancy was probably due to the fact that these were single 
case-control studies with small sample sizes.22 In addition, 
when the researchers analyzed all eight published studies on 
the EGF polymorphism and HCC risk, they found that the 
61G allele was a risk factor for HCC, while the 61A allele 
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Figure 3 (A) DFs based on egF snP in hcc patients and (B) Os based on egF snP in hcc patients.
Abbreviations: DFS, disease-free survival; EGF, epidermal growth factor; HCC, hepatocellular carcinoma; NS, not significant; OS, overall survival; SNP, single nucleotide 
polymorphism.
Table 5 Univariate and multivariate analysis of clinicopathological factors for overall survival
Variables Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
sex (male vs female) 1.23 (0.62–2.80) 0.567
age ($65 vs ,65) 1.30 (0.80–2.14) 0.287
Virus (hcV vs hBV) 1.28 (0.70–2.54) 0.432
histological differentiation (well vs others) 0.72 (0.37–1.31) 0.298
Tumor size ($3 cm vs ,3 cm) 2.12 (1.20–4.01) 0.009 1.92 (1.03–3.80) 0.040
Tumor multiplicity (multiple vs solitary) 1.68 (0.98–2.79) 0.060
Pattern of fibrous growth (infiltrative vs expansive) 1.89 (0.98–3.38) 0.057
Formation of fibrous capsule (present vs absent) 0.81 (0.18–1.40) 0.431
Capsular infiltration (present vs absent) 0.81 (0.50–1.34) 0.410
septal formation (present vs absent) 0.72 (0.54–1.56) 0.716
Vascular invasion (present vs absent) 2.61 (1.53–4.35) ,0.001 2.48 (1.17–5.36) 0.018
Pathological stagea (i or ii vs iii or iV) 0.60 (0.37–0.99) 0.048 0.73 (0.34–1.49) 0.401
aFP level ($20 ng/ml vs ,20 ng/ml) 1.86 (1.13–3.15) 0.015 1.81 (1.08–3.10) 0.024
egF genotype (a/g vs a/a) 1.52 (0.54–6.35) 0.468
egF genotype (g/g vs a/a) 1.32 (0.47–5.52) 0.633
egF mrna expression ($median vs ,median) 0.83 (0.50–1.37) 0.469
Notes: independent prognostic factors were analyzed with the cox proportional hazards regression model. aaccording to TnM staging by the liver cancer study group 
of Japan.
Abbreviations: AFP, alpha-fetoprotein; CI, confidence interval; EGF, epidermal growth factor; HBV, hepatitis B virus; HCV, hepatitis C virus; OR, odds ratio; mRNA, 
messenger ribonucleic acid; TnM, tumor, node, metastasis.
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was protective. Not surprisingly, the A/A genotype occurs in 
less than 10% of Asians and African Americans but is present 
in roughly 30% of Caucasians.
It is difficult to explain why the risk of developing HCC 
is higher in patients with the A/G genotype rather than with 
the G/G genotype. One would expect that risk of HCC would 
increase with the number of copies of the G allele; however, 
it has been observed occasionally, in other studies, that the 
OR was higher for A/G patients.2,14,20 We suspect that this 
might be due to relatively small sample sizes. Regardless, the 
A/G and G/G patients had a higher risk of developing HCC 
than the patients with the A/A genotype, in our  Japanese 
population. In addition, the ORs that we report here are 
higher than those observed in studies examining other poly-
morphisms,23–25 and this observation might suggest that the 
EGF SNP strongly contributes to the development of HCC. 
Also, given that Japan is an insular country and therefore 
a genetically isolated area,26 the high risk identified by the 
EGF SNP in this Japanese population might suggest for more 
disease specificity. Thus, our observations overall strengthen 
the previous assertion that the EGF SNP is associated with 
the development of HCC.
Of note, when the analysis was limited to patients with 
HCV and adjusted for age and sex, the risk of developing 
HCC increased dramatically in the A/G and G/G patients. 
This finding is of particular importance as HCV is the main 
risk factor for HCC in Japan. In addition, several recent 
mechanistic studies support this finding. First, EGFR was 
recently shown to be a host factor for HCV cellular entry 
when it was found that EGFR signaling leads to assembly 
of the host tetraspanin receptor complex.27,28 The ligands 
that activate EGFR, especially EGF, therefore increase HCV 
cellular entry,27 and the EGF SNP is known to increase liver 
EGF levels.2
The association between the EGF genotype and prog-
nosis so far has not been described in HCC patients and 
remains controversial in other malignancies, such as glioma 
and esophageal carcinoma.29–31 In this study, no statistical 
association was found between the EGF genotype and both 
disease-free and overall survival, in HCC patients. This result 
could be explained by the fact that the prognosis of HCC, 
as opposed to other malignancies, is subject to various indi-
vidual conditions, such as cirrhosis, leading to multicentric 
carcinogenesis and residual liver function.32 Interestingly, 
EGF is part of a gene expression signature associated with 
poor overall survival in HCC patients who have had a resec-
tion and in cirrhosis patients.33,34 This signature was derived 
from the surrounding nontumoral liver tissue and might help 
explain why the increased tumoral EGF expression seen in 
our A/G and G/G patients was not associated with survival. It 
might be that EGF expression alone is not powerful enough 
to predict prognosis, or it could be that EGF expression in 
the surrounding, nontumoral tissue will have greater prog-
nostic value. Consistent with this, Falleti et al35 reported 
that the EGF genotype associates with advanced fibrosis at 
a young age in HCV patients. They hypothesized that the 
EGF polymorphism is responsible for a more rapid disease 
progression early in the course of HCV infection, which 
would be consistent with its role in cellular entry.
In conclusion, the allelic frequencies of the EGF 
polymorphism in Japanese patients were similar to those 
reported previously for other high-risk HCC groups, includ-
ing Chinese and African Americans. The A/G and G/G 
genotypes were associated with an increased risk of HCC, 
especially in HCV patients, in whom increased EGF levels 
might lead to a more rapid disease progression. We suggest 
that more intensive follow up of HCV patients with the G 
allele might lead to earlier diagnosis and better outcomes 
for HCC.
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